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INTRODUCTION
Lower urinary tract symptoms (LUTS) are known to be closely 
related to benign prostatic enlargement, benign prostatic ob-
struction (BPO), and benign prostatic hyperplasia (BPH). Ac-
cordingly, the “static” prostate enlargement determined by the 
Original Article
https://doi.org/10.5213/inj.1732732.366
pISSN 2093-4777 · eISSN 2093-6931
Vo
lum
e 19 | N
um
b
er 2 | June 2015   pages 131-210
IN
J
IN
T
E
R
N
AT
IO
N
A
L 
N
E
U
R
O
U
R
O
LO
G
Y
 JO
U
R
N
A
L
Official Journal of 
Korean Continence Society / Korean Society of Urological Research / The Korean Children’s Continence 
and Enuresis Society / The Korean Association of Urogenital Tract Infection and Inflammation
einj.org
Mobile Web
pISSN 2093-4777
eISSN 2093-6931
IN
T
E
R
N
AT
IO
N
A
L  N
E
U
R
O
U
R
O
LO
G
Y
  JO
U
R
N
A
L
Purpose: To assess the impact of periurethral calcification (PUC) according to its location on uroflowmetric parameters and 
urinary symptoms in patients with small prostate volume (PV).
Methods: Records were obtained from a prospectively maintained database of first-visit men with lower urinary tract symp-
toms (LUTS). Patients whose PV was >30 mL were excluded to elucidate more clearly the impact of PUC on LUTS. A total of 
539 patients were enrolled in the study. The prostatic urethra was examined by transrectal ultrasonography for PUC, and the 
location of PUC was divided into 3 areas (proximal, mid, and distal).
Results: The characteristics according to the location of PUC were compared using a 1-way analysis of variance test. The Total 
International Prostate Symptom Score (IPSS), postmicturition symptoms, and overactive bladder symptom score (OABSS) 
differed significantly among the groups. In the propensity score matching analysis, the proximal- and distal-PUC groups did 
not have a significantly different urinary flow rate or symptom score when compared to their matched control groups. How-
ever, the mid-PUC group had significantly worse urinary symptoms than its matched control group (total IPSS [P=0.001], 
voiding symptoms [P=0.002], storage symptoms [P=0.041], and OABSS [P=0.015]). The peak urinary flow rate was also 
lower in the mid-PUC group with borderline significance (P=0.082). On multivariate linear regression analysis, mid-PUC 
was independently associated with IPSS and OABSS (P=0.035 and P=0.011, respectively). 
Conclusions: Only mid-PUC was associated with symptom severity in men with LUTS and a small PV. Our findings suggest 
that mid-PUC could be a potential causal factor of LUTS, and the midportion of the prostatic urethra might play a pivotal role 
in the process of micturition.
Keywords: Urethra; Prostatic hyperplasia; Lower urinary tract symptoms; Calculi; Inflammation
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tone of the prostate and “dynamic” alpha-receptor-mediated 
smooth muscle tension are regarded as 2 major components 
connected to male LUTS [1]. However, in clinical practice, ap-
proximately half of LUTS patients have a relatively small pros-
tate (30 mL or less) [2] and undoubtedly have a weaker correla-
tion with those volume factors. Moreover, urodynamic findings 
showed that only half of the patients demonstrated bladder 
outlet obstruction in LUTS patients with a small prostate vol-
ume (PV), indicating the heterogeneity of this disease [3]. For 
this reason, several anatomical prostatic factors, such as the 
transitional zone index (TZI) and prostatic urethral angle 
(PUA), rather than simple volume parameters, have been inves-
tigated [4,5].
 Male LUTS has a multifactorial etiology, and, recently, a third 
major hypothetical factor has been proposed, prostatic inflam-
mation [1]. In particular, inflammation of the periurethral area, 
which ultimately induces periurethral fibrosis, could maximize 
induction of LUTS [6]. Although the etiology of prostatic calci-
fication remains unclear, calcification of the urethra can, similar 
to other tissues, result in urethral stiffness [7,8]. Based upon 
this theoretical hypothesis, we have previously demonstrated 
the significant impact of periurethral calcification (PUC) on 
LUTS.
 To more clearly elucidate the impact of PUC on LUTS, the 
volume factor was purely confined in this study (PV≤30 mL). 
Herein, we evaluated the association between PUC, urinary 
symptoms, and uroflowmetric measurements with a small PV 
and further analyzed the clinical impact of PUC according to 
its location (proximal, mid, or distal) on the prostatic urethra.
MATERIALS AND METHODS
Patient Cohort
This study is a retrospective analysis of a prospectively main-
tained database of male patients with LUTS/BPH who had their 
initial visit at our outpatient clinic between April 2010 and April 
2013. During this period, 1,199 patients were registered in our 
database. A detailed medical history was obtained for patients 
aged 40 to 80 years after excluding the following conditions that 
are potential LUTS inducing factors: (1) clinically apparent 
bladder or prostate cancer, (2) neurologic disease that could in-
fluence voiding symptoms, (3) uncontrolled diabetes mellitus, 
(4) history of a previous lower urinary tract surgery, (5) history 
of radiotherapy to the pelvis, and (6) urinary tract infections. A 
total of 1,030 patients were initially enrolled, and those with a 
total prostate volume (TPV) >30 mL were excluded. Finally, 
539 patients were eligible for the final analysis.
Good Clinical Practice Protocols
The study was performed in accordance with applicable laws 
and regulations, good clinical practices, and ethical principles 
as described in the Declaration of Helsinki. This study protocol 
was approved by the Institutional Review Board of Gangnam 
Severance Hospital (approval number: 3-2016-0149). Written 
informed consent was obtained from all subjects.
Assessment of Urinary Symptoms and Uroflowmetric 
Measurements
LUTS were evaluated using the International Prostate Symptom 
Score (IPSS), quality of life score, and overactive bladder symp-
tom score (OABSS). The total IPSS was subcategorized into 
voiding, storage, and postmicturition symptom scores. For uro-
flowmetric measurements, maximum urinary flow rate (Qmax) 
and postvoid residual volume (PVR) were evaluated. Both uro-
flowmetric and PVR measurements were repeated if the voided 
volume was <125 mL. The assessment was made using Blue-
tooth uroflowmetry (Urodyn+; Mediwatch Ltd., Rugby, UK) 
and a bladder scanner (BioCon-500; MCube Technology Co., 
Ltd, Seoul, Korea).
Assessment of Prostatic Anatomical Factors
Transrectal ultrasonography (TRUS) was performed on all sub-
jects (Prosound Alpha 5 SV, Hitachi Aloka Medical, Ltd., To-
kyo, Japan [between April 2010 and November 2012]; Pro Fo-
cus 2202 Ultrasound System, BK-Medical, Herlev, Denmark 
[between December 2012 and April 2013]). TPV and transi-
tional zone volume (TZV) were measured using the prolate el-
lipsoid formula (height ×width ×length ×π/6). The TZI was 
calculated according to the formula, TZI=TZV/TPV [9].
 Prostatic calculi were viewed and scored in both axial and 
sagittal planes. Two investigators (JHH and JKK) independent-
ly determined the degree of prostatic calculi. Disagreement be-
tween the 2 investigators was resolved by a discussion with an-
other investigator (KSC). The prostatic urethra was examined 
along the midsagittal plane. PUC was assessed for all of the sag-
ittal images taken serially on TRUS, and we defined PUC as 
prostatic calcification that is within 2 mm of the prostatic ure-
thra on the sagittal view of TRUS [10]. According to the classi-
cal definition demonstrated by Harada et al. [11], prostatic cal-
cification demonstrating a burden or mass along the prostatic 
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urethra was considered to be a clinically significant PUC, while 
the absence of or a small solitary calcification was considered to 
be an insignificant PUC. Overall PUC was determined based 
on the proportion of the urethra with significant calcification to 
the entire prostatic urethral length. The location of the PUC 
was divided into 3 consecutive nonoverlapping periurethral ar-
eas (proximal 1/3, middle 1/3, and distal 1/3) (Fig. 1). 
 
Statistical Analysis
A 1-way analysis of variance (ANOVA) test was applied to 
compare the clinical characteristics of the 3 different PUC 
groups according to the location of the PUC. To clarify our 
comparisons, we targeted the patients that had PUC only in 
one location (proximal PUC only, mid-PUC only, or distal 
PUC only). Using a propensity score matching analysis, the vol-
ume factor (TPV), age, and voided volume were matched, and 
each PUC group was sequentially compared to their matched 
control group using a paired t-test. All statistical analyses were 
performed using R software (version 3.0.3, R Foundation for 
Statistical Computing, Vienna, Austria; http://www.r-project.
org). A P-value <0.05 was considered statistically significant, 
and all statistical tests were 2-sided.
RESULTS
As the result of interobserver reliability measurement, we re-
corded intraclass correlation coefficients for a PUC of 0.981 
(95% confidence interval, 0.978–0.983), which indicates an ex-
cellent reliability. In terms of the patient baseline characteristics, 
the mean patient age was 60.03 ±10.00 years, and the mean 
TPV and mean TZV were 23.05±4.12 and 9.71±2.88, respec-
tively. On the midsagittal plane, overall PUC was classified into 
3 groups. The numbers of patients with no, mild, and moderate 
to severe PUC were 351 (65.1%), 126 (23.4%), and 62 (11.5%), 
respectively. Regarding the distribution of PUC location, the 
number of patients in the proximal-, mid-, and distal-PUC 
groups were 79 (14.7%), 124 (23.0%), and 69 (12.8%) (Table 1). 
 We included 117 out of 539 patients (21.7%) who had only 
one location with PUC in the 1-way ANOVA test. The proxi-
mal-PUC only (p-PUC), mid-PUC only (m-PUC), and distal-
PUC only (d-PUC) groups were composed of 35, 63, and 19 
patients, respectively. The 3 groups significantly differed in the 
Fig. 1. Representative images of the 3 groups of periurethral calcification (PUC) according to their location on the midsagittal plane 
during transrectal ultrasonography. Midsagittal plane demonstrating the trace of the urethra without PUC (A), proximal PUC (B), 
mid-PUC (C), and distal PUC (D).
A B
C D
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total IPSS, postmicturition symptoms, and OABSS, and the m-
PUC group displayed the worst symptom scores in all fields, 
followed by the p-PUC and d-PUC groups. Total IPSS for the m-
PUC group was 19.3±7.5, compared to 16.5±6.0 and 14.7±7.2 
for the p-PUC and d-PUC groups, respectively (P=0.026). Post-
micturition symptoms were 3.0±1.6 vs. 2.3±1.5 and 2.1±1.4, re-
spectively (P=0.016). OABSS was 5.9±3.8 vs. 4.1±3.3 and 3.8± 
2.1, respectively (P =0.017). There were no differences in the 
mean patient age or total PV among the three groups (Table 2).
 Propensity score matching analysis was performed for each 
group (p-PUC, m-PUC, and d-PUC). Neither the p-PUC or d-
PUC groups demonstrated any significant impact on urinary 
symptoms or Qmax when compared to their matched control 
group (Tables 3, 4). However, the m-PUC group displayed sig-
nificantly worse urinary symptoms than its matched control 
group (Total IPSS [19.3±7.5 vs. 16.2±6.8, P=0.001], voiding 
symptoms [8.7±4.0 vs. 7.3±3.6, P=0.002], storage symptoms 
[7.5±3.5 vs. 6.4±3.3, P=0.041], and OABSS [5.9±3.8 vs. 4.2±3.2, 
P=0.015]). Qmax was also lower in the m-PUC group, with 
borderline significance (13.7±5.3 and 15.7±7.9, P=0.082) (Ta-
ble 5).
 To confirm the independent clinical power of PUC, we per-
formed univariate and multivariate linear regression analysis 
following propensity score matching analysis. For the multivar-
iate model, variables proven significant in univariate analysis 
were taken into account. Multivariate linear regression analysis 
showed age, TZI, and m-PUC significantly affected IPSS total 
(P=0.002, P=0.016, and P=0.035, respectively). For the OABSS, 
only age and m-PUC were independently correlated (P<0.001 
and P=0.011, respectively) (Table 6).
DISCUSSION
Male LUTS associated with a small PV represents approximate-
ly half of the total LUTS patients [2]. This ratio was also consis-
tent with our data (539 of 1,030, 52.3%). Because the number of 
LUTS patients has increased over time, there have been several 
efforts to search for the significant prostatic anatomical param-
eters capable of predicting male LUTS, such as intravesical 
prostatic protrusion, TZI, presumed circle area ratio, peripheral 
zone thickness, and PUA. However, despite the high proportion 
of patients that have a small PV (<30 mL), only PUA and TZI 
have been shown to be independent factors affecting LUTS in 
this group [4,5].
 LUTS in patients with a small PV is being highlighted due to 
the difference in its characteristics compared to those of general 
LUTS/BPH. Small PV LUTS patients are not likely to have 
BPO. The classical dynamic and static components of the pros-
tate cannot explain the exact pathophysiology of small PV 
LUTS. The 5-alpha-reductase inhibitor finasteride has been 
shown in large cohort studies to have unsatisfactory results in 
small PV patients [12]. Alpha blockers play a role in reducing 
dynamic obstruction; however, outcome data is variable regard-
ing small PV, making achieving a reliable assessment of the ef-
fects of medical treatments more difficult [13].
 We focused on prostatic inflammation in small PV. For gen-
eral LUTS/BPH, prostatic inflammation in a previous study 
was correlated with symptomatic progression, risk for urinary 
Table 1. Clinical features of subjects (n=539)  
Variable Value
Age (yr) 60.03±10.00
Comorbidities
   Hypertension
   Diabetes mellitus
  
179 (33.2)
91 (16.9)
Serum prostate-specific antigen (ng/mL) 1.29±1.54
IPSS
   Total
   Voiding symptoms
   Storage symptoms
   Postmicturition symptoms
   Quality of life score
  
16.61±7.22
7.48±3.86
6.58±3.40
2.55±1.60
3.90±1.11
OABSS 4.54±3.20
Uroflowmetry
   Qmax (mL/s)
   Voided volume (mL)
   Postvoid residual volume (mL)
15.25±7.53
285.33±159.00
25.44±39.11
Prostate volume parameters
   Total prostate volume (mL)
   Transitional zone volume (mL)
   Transitional zone index
  
23.05±4.12
9.71±2.88
0.42±0.97
Prostatic calcification
   Overall periurethral calcification
      None
      Mild
      Moderate to severe
   Location of periurethral calcificationa)
      Proximal periurethral calcification
      Mid periurethral calcification
      Distal periurethral calcification
  
  
351 (65.1)
126 (23.4)
62 (11.5)
  
79 (14.7)
124 (23.0)
69 (12.8)
Values are presented as mean±standard deviation or number (%).
IPSS, International Prostate Symptom Score; OABSS, overactive blad-
der symptom score; Qmax, maximum urinary flow rate.
a)A number of patients have been counted multiple times. 
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retention, and the need for surgery [14]. Complete understand-
ing of the inflammatory process and its pathogenesis is still in 
progress; however, inflammation is emerging as the new target-
ed process for male LUTS [15]. Within the prostate’s anatomic 
structure, inflammation of the periurethral region, leading to 
periurethral fibrosis, was recently highlighted as a LUTS-induc-
ing factor [6,16-18]. Cantiello et al. [19] assessed periurethral 
tissues from radical prostatectomy specimens and suggested 
that fibrotic changes in periurethral prostatic tissues induced by 
prostate inflammation may eventually promote urethral stiff-
ness and LUTS. Kim et al. [16] tested the association between 
prostate elasticity and LUTS with a novel palpation system (In-
Table 2. Comparisons of clinical features according to location of periurethral calcification (PUC)    
Variable Total (n=117) Proximal-PUC (n=35) Mid-PUC (n=63) Distal-PUC (n=19) P-value
Age (yr) 62.0±9.9 61.7±10.5 61.7±9.7 63.6±10.0 0.752
Serum prostate-specific antigen (ng/mL) 1.2±1.2 1.2±1.1 1.1±1.0 1.6±1.6 0.153
IPSS
   Total
   Voiding symptoms
   Storage symptoms
   Postmicturition symptoms
   Quality of life score
  
17.7±7.2
8.0±3.8
7.1±3.6
2.7±1.6
4.1±1.1
  
16.5±6.0
7.4±3.5
6.8±3.7
2.3±1.5
4.1±1.0
  
19.3±7.5
8.7±4.0
7.5±3.5
3.0±1.6
4.1±1.1
  
14.7±7.2
6.8±3.5
5.9±3.1
2.1±1.4
3.7±1.0
  
0.026
0.083
0.186
0.016
0.355
OABSS 5.0±3.6 4.1±3.3 5.9±3.8 3.8±2.1 0.017
Uroflowmetry
   Qmax (mL/s)
   Voided volume (mL)
   Postvoid residual volume (mL)
14.0±6.8
254.9±136.9
26.3±45.0
14.1±8.5
282.2±141.0
26.4±35.6
13.7±5.3
238.1±111.9
28.0±52.8
15.2±7.7
260.0±193.9
20.1±31.1
0.696
0.308
0.801
Prostate volume parameters
   Total prostate volume (mL)
   Transitional zone volume (mL)
   Transitional zone index
  
23.1±4.5
10.1±3.0
0.4±0.1
  
22.5±4.4
9.6±2.8
0.4±0.1
  
23.9±4.2
10.7±3.1
0.4±0.1
  
21.6±5.3
9.0±2.4
0.4±0.1
  
0.113
0.036
0.394
Values are presented as mean±standard deviation.
IPSS, International Prostate Symptom Score; OABSS, overactive bladder symptom score; Qmax, maximum urinary flow rate.
Table 3. Matched cohorts of proximal periurethral calcification (PUC) present vs. absent groups using propensity scores  
Variable Total (n=70)
Matched Cohort
Proximal PUC (-) (n=35) Proximal PUC (+) (n=35) P-value
Age (yr) 62.0±10.8 62.4±11.1 61.7±10.5 0.695
Total prostate volume (mL) 22.7±4.4 23.0±4.3 22.5±4.4 0.688
Transitional zone volume (mL) 9.4±2.7 9.2±2.6 9.6±2.8 0.593
Transitional zone index 0.4±0.1 0.4±0.1 0.4±0.1 0.157
Qmax (mL/sec) 14.2±7.9 14.3±7.2 14.1±8.5 0.929
Voided volume (mL) 279.6±147.1 277.1±155.0 282.2±141.0 0.861
Postvoid residual volume (mL) 28.3±35.5 30.2±35.7 26.4±35.6 0.687
IPSS
   Total
   Voiding symptoms
   Storage symptoms
   Postmicturition symptoms
   Quality of life score
  
16.8±6.7
7.5±3.6
6.8±3.6
2.5±1.5
4.0±0.9
  
17.0±7.4
7.6±3.8
6.8±3.5
2.6±1.4
4.0±0.8
  
16.5±6.0
7.4±3.5
6.8±3.7
2.3±1.5
4.1±1.0
  
0.780
0.877
0.973
0.434
0.681
OABSS 4.7±3.4 5.3±3.4 4.1±3.3 0.180
Values are presented as mean±standard deviation.         
Qmax, maximum urinary flow rate; IPSS, International Prostate Symptom Score; OABSS, overactive bladder symptom score.  
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denter) and showed that prostate elasticity was independently 
associated with voiding symptoms. Based on these studies, 
periurethral fibrosis can be assumed to be a cause of LUTS 
through decreased urethral flexibility while compromising the 
ability of the prostatic urethra to enlarge to adequately accom-
modate urinary flow during micturition [10,19].
 Prostatic calcification has a pathological connection with 
prostatic inflammation and fibrosis. The etiology of prostatic 
calcification is not yet fully understood; however, studies at the 
molecular level have shown that calcifications induced by in-
flammation generate a microenvironment that drives more in-
flammatory change, characterized by lymphocyte infiltration, 
Table 4. Matched cohorts of distal periurethral calcification (PUC) present vs. absent groups using propensity scores   
Variable Total (n=38)
Matched Cohort
Distal PUC (-) (n=19) Distal PUC (+) (n=19) P-value
Age (yr) 62.8±10.4 62.0±11.1 63.6±10.0 0.449
Total prostate volume (mL) 21.4±5.0 21.2±4.8 21.6±5.3 0.670
Transitional zone volume (mL) 9.3±2.5 9.6±2.6 9.0±2.4 0.360
Transitional zone index 0.4±0.1 0.5±0.0 0.4±0.1 0.110
Qmax (mL/sec) 14.1±7.4 12.9±7.2 15.2±7.7 0.186
Voided volume (mL) 240.1±161.1 220.2±122.2 260.0±193.9 0.436
Postvoid residual volume (mL) 19.3±28.1 18.6±25.6 20.1±31.1 0.857
IPSS
   Total
   Voiding symptoms
   Storage symptoms
   Postmicturition symptoms
   Quality of life score
  
15.8±7.5
7.4±3.8
6.2±3.2
2.2±1.5
3.8±1.1
  
16.8±7.8
8.0±4.1
6.4±3.3
2.4±1.7
3.9±1.2
  
14.7±7.2
6.8±3.5
5.9±3.1
2.1±1.4
3.7±1.0
  
0.451
0.377
0.633
0.578
0.680
OABSS 4.3±2.8 4.8±3.4 3.8±2.1 0.214
Values are presented as mean±standard deviation.         
Qmax, maximum urinary flow rate; IPSS, International Prostate Symptom Score; OABSS, overactive bladder symptom score.  
Table 5. Matched cohorts of mid-periurethral calcification (PUC) present vs. absent groups using propensity scores   
Variable Total (n=126)
Matched Cohort
Mid-PUC (-) (n=63) Mid-PUC (+) (n=63) P-value
Age (yr) 61.4±9.5  61.1±9.3  61.7±9.7 0.755
Total prostate volume (mL) 24.1±3.8  24.3±3.3  23.9±4.2 0.455
Transitional zone volume (mL) 10.5±2.8  10.4±2.6  10.7±3.1 0.499
Transitional zone index 0.4±0.1   0.4±0.1   0.4±0.1 0.369
Qmax (mL/sec) 14.7±6.8  15.7±7.9  13.7±5.3 0.082
Voided volume (mL) 257.9±134.7 277.7±152.5 238.1±111.9 0.124
Postvoid residual volume (mL) 30.3±48.4  32.5±43.8  28.0±52.8 0.611
IPSS
   Total
   Voiding symptoms
   Storage symptoms
   Postmicturition symptoms
   Quality of life score
  
17.7±7.3
8.0±3.9
6.9±3.5
2.8±1.6
4.0±1.0
  
 16.2±6.8
  7.3±3.6
  6.4±3.3
  2.6±0.6
  3.9±0.9
  
 19.3±7.5
  8.7±4.0
  7.5±3.5
  3.0±1.6
  4.1±1.1
  
0.001
0.002
0.041
0.055
0.137
OABSS 5.1±3.6   4.2±3.2   5.9±3.8 0.015
Values are presented as mean±standard deviation.         
Qmax, maximum urinary flow rate; IPSS, International Prostate Symptom Score; OABSS, overactive bladder symptom score.  
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cytokine activation, and release of reactive oxygen species [20-
22]. Prostatic calcification is not synonymous with prostatic fi-
brosis, but chronic inflammation can eventually lead to fibrosis-
related calcification, a proven phenomenon in other tissues [23-
25]. If inflammation induces urethral calcification, this process 
can, as shown in other tissues, affect urethral stiffness [7,8].
 In this study, PUC was proposed as an independent risk fac-
tor for male small PV LUTS. Notably, this is the first trial to as-
sess PUC according to its location and to demonstrate that 
PUC is independently associated with worse urinary symptom 
scores in a small PV. We previously reported that overall PUC 
was associated with Qmax, total IPSS, and storage symptoms in 
TPV [10]. However, in the current study overall PUC was only 
associated with the Qmax when limited to small PV (data not 
shown). Taking these findings together, we can deduce that 
periurethral inflammation has a more synergistic effect on male 
LUTS if accompanied by a larger prostate. 
 The degree of overall PUC according to TPV in those with a 
small PV was similar (none, mild, moderate to severe: 63.5%, 
22.6%, and 13.9% vs. 65.1%, 23.4%, and 11.5%). The mean age 
difference between the 2 trials was approximately 2 years, and 
the mean PV difference was approximately 10 g (i.e., the TPV 
group was older and had larger prostates).
 For the proximal PUC, we considered this presentation to be 
inflammation and fibrosis of the proximal prostatic urethra and 
bladder neck, which could hypothetically play a major role in 
micturition initiation. In clinical practice, primary bladder neck 
obstruction without BPH is related to a reduced flow rate and 
higher urinary symptom scores by disturbing bladder neck re-
laxation during the voiding phase. Its etiology varies, and one 
of the etiologies is known to be an inflammatory-induced fi-
brotic change [26,27]. However, in this study we failed to prove 
any clinical relevance of the p-PUC group with the peak uri-
nary flow rate or urinary symptoms. A future study should be 
undertaken to evaluate the potential relationship between blad-
der neck calcification and endoscopically proven bladder neck 
obstruction.
 Additionally, the d-PUC group also failed to show any signif-
icant impact on the peak urinary flow rate or urinary symptom 
scores. In the one-way ANOVA test comparing the uroflow-
metric measurements and urinary symptom scores among the 
3 different PUC groups (p-PUC, m-PUC, and d-PUC), the pa-
tient with distal-PUC typically had the best outcomes com-
pared to the p-PUC and m-PUC groups. From this result, con-
versely, we provisionally conclude that the distal portion of the 
prostatic urethra has a minimal role in the micturition process 
compared to the proximal and midportions.
 Distinct from the p-PUC and d-PUC groups, the m-PUC 
group showed a significant impact on most of the urinary symp-
toms in patients with a small PV. There have been several stud-
ies demonstrating urethral movement during the voiding 
phase. Ukimura et al. [28] reported that the prostatic urethra is 
pulled upward in a ventral direction toward the pubic bone 
during voiding. This theory is consistent with PUA mechanics; 
the urethra tends to reduce its resistance by reducing the PUA 
by moving ventrally, consequently straightening the urethra. 
However, if the PUA remains high due to limited movement 
induced by PUC, energy loss proportional to the PUA could 
Table 6. Multivariate linear regression analysis of prostatic parameters for IPSS and OABSS  
Variable
International Prostate Symptom Score Overactive bladder symptom score
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
Standardized 
coefficient β P-value
Standardized 
coefficient β P-value
Standardized 
coefficient β P-value
Standardized 
coefficient β P-value
Age 0.165 <0.001 0.136 0.002 0.269 <0.001 0.246 <0.001
TPV -0.017 0.714 - - -0.028 0.537 - -
TZV 0.099 0.027 -0.065 0.383 0.069 0.123 - -
TZI 0.151 0.001 0.181 0.016 0.109 0.015 0.072 0.097
p-PUC 0.042 0.355 - - 0.021 0.647 - -
m-PUC 0.116 0.01 0.094 0.035 0.145 0.001 0.111 0.011
d-PUC -0.025 0.578 - - 0.011 0.8 - -
IPSS, International Prostate Symptom Score; OABSS, overactive bladder symptom score; TPV, total prostate volume; TZV, transitional zone volume; TZI, 
transitional zone index; p-PUC, proximal periurethral calcification; m-PUC, mid periurethral calcification; d-PUC, distal periurethral calcification.
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occur during micturition and could result in a decrease in urine 
velocity, consequently causing LUTS [4,29]. Theoretically, due 
to the mid-PUC leading to midperiurethral fibrosis, the PUA 
could have a fixed tone, causing ineffective voiding, and ulti-
mately causing LUTS. From the urethral dynamic mechanics 
proven above, we believe these significant findings regarding 
the mid-PUC indirectly support the idea that the midportion 
of the prostatic urethra is a clinically important region with re-
spect to male LUTS.
 However, our study has some limitations. First, this study in-
cluded a small number of subjects; thus, further study with a 
larger cohort is needed to draw a more objective and concise 
conclusion regarding PUC in patients with a small PV. Al-
though PUC, inflammation, and fibrosis are hypothetically 
mutually related, it remains unclear whether these 3 factors 
have the same impact on LUTS or not [10]. Studies on the dif-
ferences in pathological prostatic tissue according to varying 
prostate PUC location are warranted. Regarding proximal 
PUC, further study is required to assess the relationship be-
tween the proximal-PUC group and bladder neck fibrosis, ac-
companied by a pathological and mechanical analysis. Further-
more, a meticulous assessment of the dynamic movement of 
the urethra is still imperative, and additional controlled pro-
spective studies regarding the effect of urethral stiffness on the 
3-dimensional movement of the urethra should be described in 
future studies. 
 In conclusion, only mid-PUC was associated with urinary 
symptom severity in men with LUTS and a small PV. Our find-
ings suggest that the mid-PUC could be a potential causal fac-
tor of LUTS, and the midportion of the prostatic urethra might 
play a pivotal role in the process of micturition. 
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